REPRESENTATIVE CLINICAL TRIALS OF IMMUNOCONJUGATES AS ANTI-SOLID TUMOR A

1983 | 1984 | 1987 | 1988 | 1989 | 1990 | 1991 | **1992** | 1993 | 1994

a vindesine-anti-
ugate in refractory
ced metastatic
carcinomas[1]

Study of antibody conjugates of daunorubicin and chlorambucil in neuroblastoma[2]

Phase I clinical trial of Xomazyme-Mel for Metastatic Melanoma[3]

Phase II clinical trial of Xomazyme-Mel for Stage III Metastatic Melanoma[4]

Clinical study of Adriamycin-Ab in breast, tongue, lung, and colon cancers[5]

Clinical study of A7-Mitomycin C and A7-neocarzinostatin in colorectal cancer[6]

Clinical studies of adriamycin, idarubicin, chlorambucil, melphalan, aminopterin, and methotrexate immunoconujgates in colorectal cancer[7]

Phase I studies of 260F9-ricin toxin A-chain for metastatic breast carcinoma[8]

Phase I trial of XomaZyme-791 in metastatic colon cancer[9]

Phase I study of Xomazyme-Mel in advanced malignant melanoma[10]

Phase I trial of XMMCO-791-RTA in colorectal cancer[11]

Phase I trial of NAcMEL-anti-colon cancer MoAbs in advanced

Phase II clinical trial of Xomazyme-Mel for Metastic Melanoma[17]

Phase I clinical trial of KSI/4-methotrexate for NSCLC[18]

KSI/4-Vinca alkaloid conjugate clinical study for adenomas[19]

Phase I clinical trial of 454A12-rRA in ovarian, mesothelial, renal, and gastrointestinal cancers[20]

Clinical trial of OVB3-PE for refractory ovarian cancer[21]

Phase I trial of XomaZyme-Mel in metastatic melanoma[22]

Chari 1992
(Ex. 1012)

Phase I/II study of XomaZyme-Mel plus Cyclosporine A in metastatic melanoma[23]

Phase I/II study of Anti-CE
bR on hepatic metastases
gastrointestinal origin[24]

Clinical studies of KS1/4
Methotrexate in NSCLC

Phase I
RT

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.